Clinical research center «BioEq» offers patients to participate in the phase III clinical study of carboplatin and paclitaxel, used with and without the PARP inhibitor, for HER-2 negative patients with metastatic or locally advanced unresectable breast cancer associated with mutation of the BRCA gene.
Investigational Product: original drug, the PARP inhibitor.
Comparator Products: carboplatin and paclitaxel.
All examinations and medications are provided on a free of charge basis. «BioEq» provides taxi for all visits, except the first one.
We invite men and women starting from 18 years old with:
- Confirmed diagnosis of metastatic or locally advanced breast cancer
- Locally advanced cancer must not be resected or effected by ionized radiation
- Suspected case of pathological or pathological generative mutations BRCA1 and/or BRCA2
- HER2 negative breast cancer
If you are interested in this research or you have questions about participation, you can contact us during the business days from 10 am to 6 pm at